



Segregation of mtDNA Throughout Human Embryofetal Development: m.3243A>G as a Model System

Sophie Monnot, Nadine Gigarel, David C Samuels, Philippe Burlet, Laetitia Hesters, Nelly Frydman, René Frydman, Violaine Kerbrat, Benoît Funalot, Jéléna Martinovic, et al.

► To cite this version:

Sophie Monnot, Nadine Gigarel, David C Samuels, Philippe Burlet, Laetitia Hesters, et al.. Segregation of mtDNA Throughout Human Embryofetal Development: m.3243A>G as a Model System. Human Mutation, 2010, 32 (1), pp.116. 10.1002/humu.21417 . hal-00602304

HAL Id: hal-00602304

<https://hal.science/hal-00602304>

Submitted on 22 Jun 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Segregation of mtDNA Throughout Human Embryofetal Development: m.3243A>G as a Model System



Journal:	<i>Human Mutation</i>
Manuscript ID:	humu-2010-0326.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	28-Oct-2010
Complete List of Authors:	<p>Monnot, Sophie; Paris Descartes University; INSERM, Unit U781; Necker Hospital, Medical Genetics</p> <p>Gigarel, Nadine; Necker Hospital, Medical Genetics</p> <p>Samuels, David; Vanderbilt University Medical Center, Molecular Physiology and Biophysics</p> <p>Burlet, Philippe; Necker Hospital, Medical Genetics</p> <p>Hesters, Laetitia; Antoine Beclere Hospital, Reproductive Medecine and Obstetrics</p> <p>Frydman, Nelly; Antoine Beclere Hospital, Reproductive Medecine and Obstetrics</p> <p>Frydman, René; Antoine Beclere Hospital, Reproductive Medecine and Obstetrics</p> <p>Kerbrat, Violaine; Antoine Beclere Hospital, Reproductive Medecine and Obstetrics</p> <p>Funalot, Benoit; Necker Hospital, Medical Genetics</p> <p>MARTINOVIC, Jéléna; Assistance Publique - Hôpitaux de Paris, APHP, Genetics</p> <p>Benachi, Alexandra; Necker Hospital, Obstetrics</p> <p>Feingold, Josué; Necker Hospital, Medical Genetics</p> <p>Munnich, Arnold; Paris Descartes University; INSERM, Unit U781; Necker Hospital, Medical Genetics</p> <p>Bonnefont, Jean-Paul; Paris Descartes University; INSERM, Unit U781; Necker Hospital, Medical Genetics</p> <p>Steffann, Julie; Paris Descartes University; INSERM, Unit U781; Necker Hospital, Medical Genetics</p>
Key Words:	mitochondrial DNA, MELAS, m.3243A>G, embryo, mitochondria

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

**Segregation of mtDNA Throughout Human Embryofetal Development:
m.3243A>G as a Model System**

Sophie Monnot,¹ Nadine Gigarel,¹ David C. Samuels,² Philippe Burlet,¹ Laetitia
Hesters,³ Nelly Frydman,³ René Frydman,³ Violaine Kerbrat,³ Benoit Funalot,¹ Jelena
Martinovic,⁴ Alexandra Benachi,⁵ Josué Feingold,¹ Arnold Munnich,¹ Jean-Paul
Bonnetfont,^{1*} Julie Steffann^{1¶}

¹Université Paris-Descartes, Unité INSERM U781, and Hopital Necker-Enfants
Malades (Assistance Publique-Hopitaux de Paris), Paris, 75015, France ; ²Center for
Human Genetics Research, Department of Molecular Physiology and Biophysics,
Vanderbilt University Medical Center, Nashville, TN 37232, USA. ³Service de
gynécologie et médecine de la reproduction, Hôpital Antoine Béchère (Assistance
Publique-Hopitaux de Paris), Clamart, 92140, France ; ⁴Service d'histo-embryologie
cytogénétique, Hopital Necker-Enfants Malades (Assistance Publique-Hopitaux de
Paris), Paris, 75015, France ; ⁵Maternité, Hôpital Necker-Enfants Malades
(Assistance Publique-Hopitaux de Paris), Paris, 75015, France

[¶] Both authors equally contributed to the work

Correspondence: *jean-paul.bonnetfont@inserm.fr

Abstract

Mitochondrial DNA (mtDNA) mutations cause a wide range of serious diseases with high transmission risk and maternal inheritance. Tissue heterogeneity of the heteroplasmy rate (“mutant load”) accounts for the wide phenotypic spectrum observed in carriers. Owing to the absence of therapy, couples at risk to transmit such disorders commonly ask for prenatal (PND) or preimplantation diagnosis (PGD). The lack of data regarding heteroplasmy distribution throughout intra uterine development however hampers the implementation of such procedures. We tracked the segregation of the m.3243A>G mutation (*MT-TL1* gene) responsible for the MELAS syndrome in the developing embryo/fetus, using tissues and cells from 8 carrier females, their 38 embryos and 12 fetuses. Mutant mtDNA segregation was found to be governed by random genetic drift, during oogenesis and somatic tissue development. The size of the bottleneck operating for m.3243A>G during oogenesis was shown to be individual-dependent. Comparison with data we achieved for the m.8993T>G mutation (*MT-ATP6* gene), responsible for the NARP/Leigh syndrome, indicates that these mutations differentially influence mtDNA segregation during oogenesis, while their impact is similar in developing somatic tissues. These data have major consequences for PND and PGD procedures in mtDNA inherited disorders.

Key words

Mitochondria, mitochondrial DNA, MELAS, NARP, respiratory chain deficiency, embryo, preimplantation genetic diagnosis

1 Introduction

Mitochondrial DNA (mtDNA, Genbank NC_001807.4) disorders are common diseases with maternal inheritance. Their high clinical variability is explained, at least in part, by variation of the mutant load (heteroplasmy) among individuals, and also across organs and tissues within an individual, so that mutant loads will surpass the tissue specific threshold, leading to the manifestation of symptom (Chinnery et al., 1997; Jeppesen et al., 2006). The usual severity of these diseases, the recurrence risk, usually high though being difficult to predict at the individual level, in offspring from heteroplasmic carriers (Chinnery et al., 1998), and the absence of efficient therapy, commonly result in a request from at-risk couples for prenatal (PND) or preimplantation diagnosis (PGD). Such procedures are however hampered by the lack of data regarding mtDNA segregation during embryofetal development.

In this respect, most available data come from animal studies. Dramatic shifts of mtDNA populations (variant/wild-type mtDNA ratio) between the mother and her offspring in cattle have suggested that a tight bottleneck might account for such a rapid segregation (Laipis et al., 1988). One important function of this bottleneck could be to ensure that new mutations will either be lost or fixed rapidly within individuals, and thus exposed to selection at the population level (Bergstrom and Pritchard, 1998; Roze et al., 2005). Studies in mice have identified the bottleneck during oogenesis (Jenuth et al., 1996), through either a reduction of mtDNA content in primordial germ cells (PGC, Cree et al., 2008), or selection of a small effective number of segregation units for mtDNA (Cao et al., 2007; Cao et al., 2009; Wai et al., 2008). There are however no available data so far regarding mutant mtDNA segregation in somatic tissues during embryofetal development in animal models.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 In humans, a small number of studies of primary oocytes carrying mtDNA
2 deletions (Marchington et al., 1998) or point mutations (Blok et al., 1997; Brown et
3 al., 2001; Marchington et al., 2010) have suggested that a bottleneck operates during
4 oogenesis. Random genetic drift appeared as the principal mechanism determining
5 the level of mutant mtDNA within primary oocytes from a carrier of the most common
6 mtDNA mutation, m.3243A>G (Brown et al., 2001). This mutation affects the *MT-TL1*
7 gene [mitochondrially encoded tRNA leucine 1 (UUA/G), MIM 590050], and is
8 responsible for the MELAS (Mitochondrial myopathy, encephalopathy, lactic acidosis,
9 and stroke-like episodes, MIM 540000, Goto et al., 1992) and diabetes-deafness
10 syndromes (MIM 520000, van den Ouweland et al., 1992; Manouvrier et al., 1995).

11 It is so far not known whether m.3243A>G segregation is governed by random
12 drift in somatic tissues during human embryofetogenesis. The few available studies
13 on m.3243A>G carrier fetuses reported a uniform distribution of mutation load among
14 different tissues from two heteroplasmic 24 and 25 week-old human fetuses
15 (Matthews et al., 1994; Cardaioli et al., 2000). Our group found similar mutant loads
16 in chorionic villi and amniocytes from 3 heteroplasmic fetuses (Bouchet et al., 2006).
17 All these data suggest that MELAS mutant molecules do not segregate much
18 **between** 10 to 25 weeks of gestation.

19 However, we have so far lacked data on the transmission of m.3243A>G by a
20 carrier to early embryos, and subsequently no information on segregation of this
21 mutation throughout the entire period of human embryofetal development has
22 existed. Thanks to our PGD and PND programs, we collected various tissues and
23 cells at various stages of development in embryos and fetuses from m.3243A>G
24 carriers, and investigated local and temporal variation of the mutant load, using a

quantification test designed to assess m.3243A>G mutant load at the single cell level.

Aggregation of our data in early embryos and fetuses, with those from a primary oocyte study in a m.3243A>G carrier (Brown et al., 2001) indicates that mtDNA segregation is governed by random genetic drift, in germ- and somatic cell lines, throughout the entire period of human intra-uterine development. The size of the bottleneck operating during oogenesis for m.3243A>G is additionally suggested to vary between individuals. Finally, comparison of the current data with those we previously reported for another common mtDNA mutation, m.8993T>G (*MT-ATP6*, ATP synthase subunit 6 gene, MIM 516060) responsible for the NARP syndrome (Neuropathy, Ataxia, Retinitis Pigmentosa, MIM 551500; Steffann et al., 2006; Steffann et al., 2007) indicates that these two mutations differentially influence mtDNA segregation during oogenesis, while their putative impact on mtDNA segregation appears quite similar in somatic cells during embryofetal development.

Patients, Materials and Methods

Patients

This study was approved by the National Ethics Committee from l'Agence de Biomedecine and all couples gave informed consent for DNA analyses in themselves and their embryos/fetuses.

PND and/or PGD analyses were carried out in 8 individuals from 7 unrelated families, heteroplasmic for the MELAS m.3243A>G mutation. The questionable predictive value of a fetal mutant load for the postnatal outcome was emphasized to all of the couples. In such situations, counseling necessarily referred to postnatal

1 data, attempting to correlate clinical outcome and mutant load (Chinnery et al., 1997;
2 Uusimaa et al., 2007; Whittaker et al., 2009), and to our personal experience with
3 PGD/PND for another mtDNA disorder, *ie* NARP (Gigarel et al., 2005; Steffann et al.,
4 2006; Steffann et al., 2007) and with PND for MELAS (Bouchet et al., 2006).
5 Accordingly, we postulated that mutant loads over 60% during prenatal life might be
6 predictive of a serious disorder, while a mutant load below 30% might hopefully be
7 associated with absence or low severity of the disease. The most complex situation
8 was a fetal heteroplasmy value in the intermediate range (30 to 60%), a common
9 finding for the MELAS m.3243A>G mutation in the post-natal period. There is indeed
10 no available data correlating intermediate mutant load in the prenatal period with the
11 postnatal outcome.

12 Seven of the 8 couples (couples 2 to 8) elected to resort to a conventional
13 PND approach at first. Couple 1 declined the option of pregnancy termination (TOP),
14 and thus directly went to PGD, that was also offered to couple 2, who had previously
15 experienced 2 TOP after PND. Both couples were informed that, at this early
16 embryonic stage (Day 3), a number of issues remained unsolved, precluding any
17 conclusive prediction on the pre/postnatal outcome of a carrier embryo. These
18 couples were offered a PND at 16 gestation weeks (GW) to confirm the PGD result in
19 case of pregnancy.

20

21 **Materials**

22 ***Postnatal period***

23 Mutant loads from carrier females were assessed from blood, and when available,
24 urine and oral mucosa samples. Single lymphocytes were isolated from patients 1, 2,
25 3, 5, and 14 as already described (Gigarel et al., 2005).

Early embryos

Patients 1 and 2 were subjected to one and three separate PGD cycles, respectively.

A standard in vitro fertilization protocol was performed and oocytes were collected and fertilized by intracytoplasmic sperm injection (ICSI).

A total of 38 embryos were analyzed. Twenty-three of these embryos were of appropriate quality, and were therefore submitted to a 2-blastomere biopsy at post-ICSI day 3 for mutant load assessment, as previously described (Gigarel et al., 2004). Briefly, under control by a binocular microscope, the blastomeres were rinsed twice in a drop of PBS supplemented with 0.1%polyvinyl alcohol (Sigma Aldrich, France), using a mouth-controlled, finely pulled glass pipette before being transferred into a transparent microcentrifuge tube containing 3 μ l of lysis buffer (Cui et al., 1989). A small volume of biopsy medium was used as a PCR negative control for each embryo in order to detect any contamination by exogenous DNA. In the 15 remaining embryos, assessment of the mutant load was performed on the embryo *in toto*. All blastomeres were separately analyzed, when possible (couple 1: embryos 1 to 3, and couple 2: embryo 13). Embryo 10 from couple 2 was cultured up to the blastocyst stage (Day 5), enabling a trophectoderm biopsy as described elsewhere (McArthur et al., 2005). The trophectoderm and inner cell mass were analyzed separately.

Late embryos and fetuses

Prenatal diagnosis was performed in 12 fetuses from 7 carrier women. Fetus 2c resulted from embryo 7 and 11 transfer after PGD (patient 2), while the remaining ones were conceived naturally. Chorionic villi (CV, n=8), amniotic fluids 1 (AF1, n=6), and 2 (AF2, n=1), were sampled at 10, 14, and 30 weeks of gestation (GW),

1 respectively. Individual fetal cells were isolated from CV and AF samples from 6
2 fetuses, as already described (Steffann et al., 2007), and analyzed separately, to
3 investigate the intercellular variation of heteroplasmy. Cord blood was collected from
4 3 fetuses at birth (fetuses 2c, 3, and 4). Postmortem analyses of various tissues were
5 carried out in two 12 week-old fetuses (fetuses 2a and 2b) and one 19 week-old fetus
6 (5b) after TOP, and in a 20 week-old miscarriage product (fetus 7a). Parental
7 informed consent was obtained for these postmortem analyses. Fetal tissues were
8 carefully dissected, and small tissue biopsies were analyzed separately. Multiple
9 samples were taken from two term placentas (fetuses 2c and 3), and two 12GW
10 placentas (fetuses 2a and 2b).

11
12 **Methods**

13 ***DNA extraction***

14 DNA was extracted from blood and tissues, using the Nucleon Bacc3 kit (Amersham
15 Biosciences, UK), and a classical phenol extraction method, respectively.

16
17 ***Quantitative analysis of the m.3243A>G mutant load***

18 MELAS mutant load was quantified using a semi-quantitative fluorescent PCR-*HaeIII*
19 restriction test.

20 Since PCR products analysis using a restriction enzyme is thought to allow the
21 possibility of errors in mutant load assessments, secondary to heteroduplex
22 formation during the PCR process (Tanno et al., 1991), we first validated our method
23 of heteroplasmy assessment using mixing experiments and standard curve analysis.
24 Wild-type and mutant plasmids were mixed to generate 10 samples, each of them
25 comprising 10⁶ mtDNA copies, with the m.3243G>A (mutant) target at concentrations

1 ranging from 1 to 100%, which were also used to determine the lowest rate of
2 mutation detection. Each sample was amplified in triplicate, using both “single cell”
3 and “tissue” methods, and PCR products were submitted to *HaeIII* digestion.

4 We furthermore ascertained the reliability of our test over a wide range of
5 mtDNA copies, from 10^2 to 10^6 , encompassing the mtDNA copy number usually
6 present in isolated cells such as lymphocytes, blastomeres and oocytes.

7 Single cells and embryos were transferred to 3µl alkaline buffer (Cui et al.,
8 1989) and lysed by 10 min heating at 65°C. PCR amplification was carried out using
9 the forward primer (5'-TGAGTTCAGACCGGAGTAATC-3') and the reverse
10 fluorescent primer (*) (5'-(6-Fam) CTTAACAACATACCCATGGC-3'). Separate
11 experimental conditions were devised for whole tissue sample and single cell/early
12 embryo analyses.

13 Tissue sample DNA (1ng) was amplified in a 30µl reaction volume containing
14 1.5U Expand Taq DNA Polymerase, 10X PCR buffer 2 (3µl, Roche Diagnostics,
15 Mannheim, Germany), 0.5µM of each primer (Proligo, Paris, France), and 2mM
16 dNTP mix (Roche Diagnostics, Germany). Initial denaturation was carried out at 97°C
17 for 7 min 20s followed by 20 cycles (97°C for 20s, 60°C for 30s, 68°C for 1min 15s)
18 and final extension of 7 min at 68°C.

19 For a single cell or embryo analysis, the PCR reaction contained 3 µl of lysis
20 buffer (lysed cell or negative control), each primer at 0.5µM, master mix 2X (12.5µl,
21 QIAGEN Multiplex PCR kit, QIAGEN S.A, Courtaboeuf, France), and double-distilled
22 water up to a 25-µl final volume. PCR programs were 15 min of denaturation at 95°C,
23 followed by 25, 26, 27, and 30 PCR cycles for whole embryos, trophoblastic cells,
24 blastomeres, and amniocytes, respectively, consisting of 30s at 94°C, 90s at 60°C
25 and 60s at 72°C, with a 30-min final extension at 60°C.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 The resulting 251-bp fluorescent PCR products (1µl) were digested for 3 hours
2 using 10 units of *HaeIII* and subsequently submitted to electrophoresis using an
3 automated genetic analyser ABI3130 (Applied Biosystems). Digestion generated 73-
4 bp and 170-bp fluorescent fragments for the mutant and wild-type species,
5 respectively. Results were analysed with the Genescan and Genotyper software
6 (Applied Biosystems). The mutant load was calculated by dividing the mutant peak
7 area (73bp) by the sum of normal (171bp) and mutant (73bp) peak areas. Cross
8 hybridization of oligonucleotide primers to nuclear DNA was ruled out by PCR
9 amplification on mtDNA-less *Rho0* cells (Parfait et al., 1998).

11 ***Ascertainment of the fetal origin of the CV/AF cells***

12 The fetal origin of single cells collected from CV, AF1, and AF2, was ascertained by
13 simultaneous analysis of parental and embryofetal DNA using nuclear (CA)_n
14 microsatellite markers (D6S436, D19S559, D19S559, D16S3395, D6S436, and
15 DXS1073 for fetus 2a, 5a, 5b, 6, 8, and 12b, respectively), enabling to check for
16 biparental contribution to the cell genotype, and the absence of fetal cell
17 contamination by maternal DNA (Gigarel et al., 2004).

18 Amplification of microsatellites markers in single cells required nested PCR.
19 The first “outer” PCR enabled simultaneous amplification of the MELAS mutation and
20 an appropriate microsatellite marker. Briefly, cells were amplified using “single-cell”
21 PCR conditions described above, as a duplex PCR reaction, using 0.5µM of each
22 primer. 3µl of the first amplification product were subsequently mixed with 22µl of
23 “inner” amplification mix, which contained inner fluorescent microsatellite primers at
24 0.5µM, master mix 2X (12.5µl, QIAGEN Multiplex PCR kit, QIAGEN S.A,

Courtaboeuf, France), and double-distilled water up to a 25µl final volume. PCR program was as described above (20 PCR cycles).

Statistical analyses

Variance analysis and calculation of inter or intra class correlation coefficients were used to analyze quantitative traits. Qualitative traits were analyzed using a Chi2 test. The 95% confidence intervals of the measurements from Patient 2 were made by fitting a Kimura distribution (Wonnapijit et al., 2008) to the 35 mutation level measurements from this patient, and then drawing 10,000 simulated sets of 35 measurements from this Kimura distribution to estimate the confidence intervals due to sample size effects (Wonnapijit et al., 2010).

Results

Sensitivity, linearity, and reproducibility of mutant load quantification

Mixing various proportions of wild type and mutant plasmids enabled us to establish that the measured level of heteroplasmy was a linear function of the expected ratio (Figure 1). The correlation coefficient for the observed vs expected proportion of mutant was 0.99 for both “single cell” and “tissue” conditions. Triplicate experiments yielded to similar results (SD<1.7%), and mutant molecules could be detected in a proportion as low as 2% of the total mtDNA amount, thus validating reproducibility and sensitivity of the assay. These results were got with a 10⁶ mtDNA copy number

In order to demonstrate an insensitivity to template input amounts for this particular method, we ascertained the reliability of our test over a wide range of mtDNA copies, from 10² to 10⁶. Results are displayed in Supp. Figure S1.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1

2 **Analysis in carrier women**

3 Mutant loads from the 8 carriers applying for MELAS PND/PGD (family 1 to 8, Table

4 1) ranged from 5 to 40%, 8 to 50%, and 15 to 80%, in leucocytes, oral mucosa cells,

5 and urinary tract cells, respectively. The lowest and highest values were consistently

6 found in white blood cells and urinary tract cells, respectively, as expected from

7 previous reports (Chinnery et al., 1997; Chinnery et al., 1999; Frederiksen et al.,

8 2006; Whittaker et al., 2009).

9 Mutant load assessment in single lymphocytes from 5 carriers showed large

10 intercellular variations, ranging from 0 to 81%, 0 to 81%, 0 to 95%, 0 to 21%, and 0 to

11 100 in patients 1, 2, 3, 5, and 14, respectively. When pooling values from all cells

12 analyzed for a given individual, average mutant load was very close to that achieved

13 from the overall lymphocyte extract recovered from a 10ml blood sample.

14 Comparison of the mean heteroplasmy rate vs one standard deviation of the

15 heteroplasmy distribution at the single-cell level for each of the five lymphocyte pools

16 ($16.2 \pm 8.6\%$) showed a 0.92 correlation coefficient ($p < 0.05$) with a positive slope

17 (1.14 ± 0.3) (Table 2 and **Supp. Figure S2**).

18

19 **Analysis in **Day 3-Day 5** embryos**

20 Thirty-eight embryos from 2 unrelated heteroplasmic women were analyzed. The

21 m.3243A>G mutant load was assessed in 31 whole embryos and 70 single

22 blastomeres (Table 3). Exogenous DNA contamination of the embryonic sample was

23 never detected in any experiment.

24 Within the whole cohort of analyzed embryos, six had no detectable mutation

25 (detection threshold: 2%). Taking into account Patient **2** only (35 embryos), the

transmission rate was 83%. None of the embryos were homoplasmic mutant. Heteroplasmy levels ranged from 5 to 77%, with an apparently homogeneous dispersion of the mutant rates among embryos. The mutant load value was similar in all blastomeres derived from a single embryo ($n = 2$ to 11) with a 6% maximal interblastomere variability. The intraclass correlation coefficient (ICC) was equal to 0.994, consistent with the high level of agreement of intra-embryo measurements, and contrasting with the inter-embryo variability. When possible, comparison of heteroplasmy levels between the whole embryo (collected at Day 5) and two of his/her blastomeres (collected at Day 3) showed a variation rate $<7\%$ in 13/16 embryos, and between 10 and 15% in the remaining ones.

When considering all embryos from patient 2, the distribution of the mutation level values was consistent with the distribution predicted from neutral drift theory (p-value of 0.53 by KS test) comparing the data against the null hypothesis of the Kimura distribution (Wonnapijit et al., 2008). When pooling mutant loads measured in each embryo from a given woman, mean values were $30 \pm 15\%$ and $32 \pm 23\%$ for patients 1 and 2, respectively. Each of these values was close to the mutant load measured in oral mucosa cell DNA from the corresponding woman (30% and 27% for patients 1 and 2, respectively).

Embryo 10 from family 2, harbouring a 13% mutant load at Day 3, was cultured up to the blastocyst stage (Day 5) and separated in 2 parts, namely, the inner cell mass and the trophectoderm. PCR failed to amplify the inner cell mass DNA, while the heteroplasmy level of the trophectoderm was consistent with the level measured in Day 3 blastomeres (15% vs 13%).

Analysis in fetuses over 10GW

1
2
3 1 Mutant loads were assessed in extraembryonic or embryonic tissues collected
4
5 2 between 10GW to term, in 12 fetuses from 7 carriers (families 2 to 8, Table 4).
6
7

8 3 One fetus did not carry the mutation in his two tested tissues (amniocytes at
9
10 4 16 GW, and cord blood at birth, fetus 4). As observed in early embryos, no fetus was
11
12 5 homoplasmic for the mutant. The mutation load ranged from 4% to 79% in the 11
13
14 6 carriers. There was no substantial variation in mutant loads assessed at various
15
16 7 stages of pregnancies until birth (Table 4). When excluding data from extra-
17
18 8 embryonic tissues (10GW trophoblast or at term placenta), m.3243A>G mutant loads
19
20 9 were identical in all tested tissues from a given fetus [mean±SD: 74.6±0.7% (3
21
22 10 tissues), 42±0.8% (5 tissues), 71±2% (5 tissues), and 78±0.9% (7 tissues) for fetuses
23
24 11 2a, 2b, 5b and 7a, respectively]. When placenta and other tissues were available at
25
26 12 the same term of gestation (3 fetuses), values were similar in two fetuses (74.6 vs
27
28 13 74% and 78 vs 78% for fetus 2a and 7a, respectively), while fetus' 2b mutant load
29
30 14 was higher in placenta than in other tissues (57±2% vs 42±2%, respectively). Multiple
31
32 15 samples in various parts of placenta, aimed at testing the mutant load distribution,
33
34 16 did not show any substantial variation in 2, 6, 10, and 18 various loci of fetuses' 2a,
35
36 17 2b, 2c, and 3 placentas, respectively (Table 4), irrespective of the gestation stage (12
37
38 18 GW or at birth).
39
40
41
42
43
44

45 19 Single trophoblastic cells (n=83) and amniocytes (n=64) were isolated from 6
46
47 20 fetuses to investigate the intercellular mutant load variation (Figure 2). Simultaneous
48
49 21 analyses of parents' and fetal cell DNAs using a polymorphic marker proved the fetal
50
51 22 origin and the absence of contamination by maternal DNA of the analyzed cells (not
52
53 23 shown). Large intercellular variations were found both in trophoblastic cells (range: 7-
54
55 24 21%, 6-38%, 23-55%, 23-70%, and 64-100%, for fetuses 5a, 6, 12b, 8, and 2a,
56
57 25 respectively), and amniocytes, either at 14 GW (range : 10-23%, 16-42%, and 52-
58
59
60

94%, for fetuses 12b, 6 and 5b, respectively), or at 30 GW (range : 9-17% and 5-28% in fetuses 5a and 12b, respectively). When pooling values from all cells analyzed for a given cell type in a given fetus, the average mutant loads were very close to those achieved from overall chorionic villi sampling (CVS) and amniotic fluid sample (AFS) mutant loads (variation<10%, Figure 2).

Comparison of the mean heteroplasmy rate vs one standard deviation of the heteroplasmy distribution at the single-cell level for each of the ten fetal cell pools ($34.3\pm 23\%$) showed a 0.81 correlation coefficient ($p<0.01$) with a positive slope (0.13 ± 0.03) (Table 2 and Supp. Figure S2).

Predictive value of a prenatal mutant load for the postnatal outcome

Assessment of the predictive value of a prenatal mutant load for the disease severity in the postnatal period is of crucial importance. A follow-up of our small cohort of patients born after PGD ($n=1$) or PND ($n=9$) provided a preliminary indication, even though for ethical reasons we could not check for the presence of the mutation in these asymptomatic children. All these children, harbouring mutant loads between 0 and 35% in prenatal period, are indeed healthy at 1 month to 5 years of age (Table 4).

Discussion

Analysis of tissues and cells from human embryos and fetuses is currently the only approach to get some insight into processes that govern maternofetal transmission of common mtDNA mutations in humans, owing to the numerous technological difficulties met in attempts at creating animal models of mitochondrial disorders

1 (Inoue et al., 2000; Fan et al., 2008). We used this approach to study the segregation
2 of m.3243A>G mtDNA molecules during human *in utero* development, thanks to our
3 PND/PGD activities, offered to carriers of this mutation.

4 These data rely on a robust, specific and sensitive assay we devised for the
5 quantification of the m.3243A>G MELAS mutation in tissues and single cells.

6 While last-cycle labeling PCR indeed is a well-established and agreed-upon
7 standard protocol for the quantification of mtDNA heteroplasmy, a major concern with
8 this approach is the need to add the labeled primer prior to the last PCR cycle. This
9 process indeed runs a significant risk of contamination of both the endogenous PCR
10 product by exogenous DNA, and of the laboratory dedicated to single cell analyses
11 by the endogenous PCR product. Such a risk, being a minor one when amplifying a
12 large amount of DNA, becomes a major hurdle to the use of this method, when
13 applied to single cell analysis.

14 We ascertained the reliability of our test over a wide range of mtDNA copies, from
15 10^2 to 10^6 . This range encompassed the mean value of mtDNA copies in
16 lymphocytes [around 150 copies, Urata et al 2008; Maagaard et al. 2006]
17 blastomeres [11 000 – 449 000 copies, Lin et al 2004] and oocytes [200 000 –
18 800 000 copies, Craven et al. 2010]. Our results demonstrated an insensitivity to
19 template input amounts for this particular method, thus validating the results of the
20 experiments carried out on various cells and tissues.

21
22 **Analysis in Day 3-Day 5 embryos**

23 To our knowledge, data on the presence of the m.3243A>G mutation at the Day 3
24 stage of embryonic development have not been reported so far. This mutation was
25 found in 32 of 38 embryos (84%) from 2 unrelated carriers. This transmission rate is

1 in agreement with a previous report on the presence of m.3243A>G in adult carrier's
2 primary oocytes (Brown et al., 2001), whose 74 of 82 oocytes (90%) were
3 heteroplasmic. A woman carrying the pathogenic mutation may thus have mutation-
4 free embryos, advocating PGD as an appropriate procedure for preventing
5 recurrence of affected offspring in carriers, at least in the mutant load range reported
6 in this study.

7 Mutant DNA molecules were constantly found to be equally distributed among
8 the various blastomeres of a carrier embryo until Day 5, in agreement with data on
9 mtDNA polymorphisms achieved in mouse (Dean et al., 2003) and human embryos
10 (Marchington et al., 2010), as well as on the m.8993T>G (NARP) mutation in human
11 (Steffann et al., 2006). Single-cell analysis thus reflects the whole embryo mutant
12 load, supporting relevance of the usual PGD procedure for assessment of the overall
13 embryo genotypic status. It is however worth noting some occasional variability (up to
14 15%) in mutant load between single cell measurements and the whole embryo. This
15 discrepancy could have arisen from either a technical artifact (such as partial loss of
16 mitochondrion during whole embryo recovery) or physiological distortion in
17 m.3243A>G segregation from Day 3 (blastomere sampling stage) to Day 5 (whole
18 embryo recovery stage). This last hypothesis is unlikely since mutant load values
19 were very close in Day 5 trophectoderm and Day 3 single-blastomeres in the only
20 embryo where both tissues were available (Table 3), additionally indicating that the
21 mtDNA molecule segregation is not skewed across embryonic and extraembryonic
22 cells (trophectoderm) at this developmental stage. Finally, inter blastomere stability of
23 the mutant load suggests that embryonic heteroplasmy determined from a single cell
24 analysis provides an accurate estimate of the whole embryo mutant load, as

1 previously reported for other mtDNA variants (Steffann et al., 2006; Craven et al.,
2 2010)

3 The m.3243A>G mutant load was found to be highly heterogeneous among
4 various embryos from a given individual, ranging from 18 to 50% and from 0 to 77%
5 in patients' 1 and 2 embryos, respectively. These values on "early" embryos are in
6 agreement again with those on primary oocytes from a m.3243A>G carrier, the
7 mutant load of which ranged from 1 to 50% (Brown et al., 2001). Two conclusions
8 can be derived from these observations.

9 The first conclusion concerns the mode of transmission of m.3243A>G from
10 the mother to her progeny. The distribution of the mutation level values among
11 Patient 2's embryos was consistent with the Kimura distribution calculated from the
12 neutral drift theory. Furthermore, an equal number of her embryos were found to
13 harbour a mutation level greater than the mean value (18 embryos) and less than the
14 mean (17 embryos). Finally, the mean level of heteroplasmy amongst all embryos
15 was very close to the heteroplasmy level seen in the mother (oral mucosal cells and
16 blood, patients 1 and 2). These data argue for random genetic drift as the
17 mechanism governing mtDNA segregation during oogenesis. This observation in
18 humans is in full agreement with the results of a study of heteroplasmy distribution in
19 the progeny of mice carrying apparently neutral BALB/c and NZB mtDNA sequence
20 variants (Jenuth et al., 1996). Assuming that blastomere analysis provides a direct
21 insight on mature oocyte mutant load, our data, gathered with those of Brown et al.,
22 suggest that mtDNA segregation is governed by a random genetic drift mechanism
23 over the whole oogenesis period.

24 The second conclusion regards the size of the bottleneck operating for
25 m.3243A>G during oogenesis (table 5). The embryos from patient 2 had a larger

1 normalized variance (Wonnapijitte et al., 2010), and therefore a smaller bottleneck
2 parameter, than the oocytes from the individual in Brown's study (Brown et al., 2001).
3 The confidence intervals did not quite overlap, indicating that there is a real
4 difference between the bottleneck sizes in these two individuals, though this
5 difference is not large. These data therefore suggest that some individual-dependent
6 parameter modulates the bottleneck size for a given mtDNA mutation.

8 **Analysis in 10 – 37 GW fetuses**

9 Very few data are available on m.3243A>G segregation during fetal development so
10 far. We looked for this mutation in 12 fetuses from 8 carriers, and aggregated these
11 data with those that we (patients 12 and 13, Table 4, Bouchet et al., 2006) and other
12 groups (patients 9 to 11, Table 4, Matthews et al., 1994; Cardaioli et al., 2000; Chou
13 et al., 2004) had previously published. Maternal m.3243A>G was passed on to 17 of
14 20 fetuses (85% transmission rate). Taking embryonic and fetal data together,
15 carriers passed on the mutation to 49 of their 58 offspring (84%, Tables 3 and 4).
16 This transmission risk fits with the MELAS transmission rate calculated from the
17 mutant load determined in buccal mucosa samples from carriers' offspring in the
18 postnatal period (Uusimaa et al., 2007). It can not be ascertained whether the 3
19 fetuses shown to be mutation-free at 10GW in the current study were mutation-free
20 embryos initially or alternatively resulted from subsequent loss of mutant mtDNA
21 molecules they carried at early embryonic stage. All fetuses but one (fetus 2c) were
22 indeed conceived out of a PGD procedure, and mutant load values at the **Day 3**
23 stage were therefore not available. Our data however argue for mutant load stability
24 throughout the entire period of embryofetal development. In fetus 2c, loads in 14GW
25 amniocytes and in term cord blood were indeed 4 and 5%, respectively, in agreement

1
2
3 1 with those assessed at early embryonic stage (embryos 7 and 11 from patient 2,
4
5 2 carrying 5 and 14%, respectively, only one of whom, -fetus 2c-, developed). We
6
7 3 similarly did not find any temporal variation of the MELAS mutant load in multiple
8
9 4 samples taken within 10 to 39 GW (Table 4 A and B).

10
11
12 5 Study of various tissues from six 12-25GW fetuses (2a, 2b, 5b, 7a, 9, 10)
13
14 6 showed a tight intertissue stability in each of them. Mutant load assessed in extra-
15
16 7 embryonic (placenta) and embryonic tissues collected at the same gestation term
17
18 8 from 4 fetuses, was found to be similar in 3 of them (2a, 7a, and 9), being higher in
19
20 9 trophoblast (57 vs 42%) from the remaining one (fetus 2b). Discrepancy between
21
22 10 trophoblast and non trophoblastic fetal tissues did not seem to result from an
23
24 11 ascertainment bias secondary to loco-regional mutant load heterogeneity within
25
26 12 placenta, recently shown to exist (Marchington et al., 2006). The heteroplasmy level
27
28 13 was indeed highly similar in six separate regions of fetus 2b placenta (Table 4). Thus,
29
30 14 this placento-fetal discrepancy might be accounted for by selection of a few cells
31
32 15 which will form the first source for the placental membranes in the partitioning
33
34 16 blastocyst. This observation additionally emphasizes that analysis of single CVS
35
36 17 sample, carried out in a PND frame, may fail to assess the fetal mutant load reliably,
37
38 18 as recently reported (Marchington et al., 2010).

39
40
41 19 The observation of tight mutant load stability, both across tissues and with
42
43 20 time, in all tested fetuses, suggests that mtDNA segregation is mainly governed by
44
45 21 random genetic drift in somatic tissues throughout the entire period of human
46
47 22 embryofetal development. Furthermore, as already noted in embryos, none of the 20
48
49 23 fetuses analyzed so far (Table 4) was found to carry a heteroplasmy rate exceeding
50
51 24 80%, over a wide range of maternal mutant loads (from 5% in WBC to 80% in urinary
52
53 25 tract cells). Whether such a 80 % value has a biological significance (i.e., a

hypothetical selection against highly mutated embryos/fetuses) remains speculative. Since mutations such as m3243A>G exhibit a relatively normal pattern of distribution around the maternal mean, it would be unlikely, given the relatively small sample size and the mean maternal mutant load value in majority below 40 % (in blood) in our series (table 1) to find embryos with greater than 80 % heteroplasmy, even in the absence of selection.

We attempted to establish at the single cell level the basis of the mutant load stability observed across fetal tissues. We thus analyzed 147 cells distributed into ten pools of trophoblastic or amniotic cells (7-30 cells per pool) collected in six unrelated fetuses within the 10-30 GW period (Figure 2). Except for one homoplasmic mutant cell (fetus 2a), all cells were heteroplasmic with a mutant load ranging from 5 to 95%. This observation is in line with the few studies available on MELAS single cells collected during the postnatal life, that indeed failed to detect mutant loads over 92% and 98% in lymphocytes (Saitoh et al., 1999) and muscle fibers (Silvestri et al., 2000), respectively. These data argue that, over a critical threshold of heteroplasmy, the resulting impact on respiratory chain function promotes fetal cell death (Sasarman et al., 2008).

When pooling values from all cells belonging to a given pool, mutant load dispersion ranged from 10 to 47% (Figure 2). The frequency distribution of single cell mutant load within each of the ten cell pools corresponded to a binomial distribution, with a median value identical or very close to the mean value of heteroplasmy, in keeping with the random genetic drift mechanism. We subsequently looked for an optional relationship between a mutation rate at the tissue (chorionic villi or amniocytes) level and the amplitude of mutant load dispersion at the single cell level in this tissue (Supp. Figure S2). A previous study using adult carrier lymphocytes had

1 indeed suggested that, the higher the proportion of mutated mtDNA molecules, the
2 wider the dispersion of heteroplasmy level (Saitoh et al., 1999). Though the number
3 of single cells analyzed was low in each pool, we however assumed that each of the
4 ten cell pools was fairly representative of the whole tissue sample, based on mean
5 mutant load variance consistently less than 10% between the cell pool and the whole
6 sample. It clearly appeared that, the higher the tissue mutant load, the larger the
7 heteroplasmy dispersion in trophoblastic and amniotic cells, even if the low number
8 of analyzed cells precluded any firm conclusion on the biological relevance of this
9 observation. We then attempted to evaluate whether such a hypothetical relationship
10 can be considered in various tissues from m.3243A>G carriers, collected in prenatal
11 and postnatal periods as well. We considered that Saitoh's study was exposed to
12 some bias in heteroplasmy assessment, due to the complex experimental procedure
13 of this study (first PCR, electrophoresis gel extraction of the PCR products, second
14 PCR, PCR products enzymatic digestion, southern blotting, and bioimager analysis).
15 Using DNA from five adult carrier females, we therefore recapitulated Saitoh's study
16 with our own method of mutant load assessment, in an effort to homogenize our
17 data. We thus found a statistically significant correlation between the mean mutant
18 load in each of the five lymphocyte pools and the heteroplasmy distribution at the
19 single cell level. Interestingly, comparison of our data in lymphocytes and fetal cells
20 showed a marked difference between curve slopes for a same range of
21 heteroplasmy, arguing for some tissue-dependence of mtDNA segregation at the cell
22 level (Supp Figure S2). These data contrast with the few available data of the
23 literature, regarding single muscle fibers in adult carriers. The latter indeed showed
24 that, the higher the mean mutant load of a cell pool, the lower the heteroplasmy
25 distribution at the cell level (Petruzzella et al., 1994; Tokunaga et al., 1994; Silvestri

et al., 2000). However, the range of mutant loads does not overlap between skeletal muscle (60-100%) and the other tissues (5-60%). Thus, assuming that the apparent relationship between mean mutant loads at a whole sample level and mutant load dispersion at the single cell level makes biological sense in all these tissues, it would remain to be seen whether the proposed tissue-dependance of such correlations is valid throughout the 0-100% range of heteroplasmy.

Comparison of prenatal and postnatal data

It is difficult to reconcile the prenatal inter-tissue stability observed in this study, and the tissue-dependance of m.3243A>G mutant loads in adult carriers, who harbour heteroplasmy rates almost constantly higher in skeletal muscle, urinary epithelial tract cells, and hair follicles, than in white blood cells (Chinnery et al., 1999; Frederiksen et al., 2006; Whittaker et al., 2009).

This tissue dependance has been suggested to result from a replicative disadvantage of cells harbouring a high mutant load, thus promoting “mutation epuration” from fast regenerating tissues. Should such a biological process operate prenatally, it could be missed out within the “short” course of a pregnancy, by reference to the very slow decrease of mean mutation level in adult white blood cells (Rajasimha et al., 2008), thus reflecting the apparent inter-tissue mutant load stability throughout the prenatal period. Alternatively, cell proliferation rate would be identical among all tissues throughout intra-uterine life, and would become tissue dependant from a fairly late postnatal period. A similar value of mutant load (65 to 70%) has indeed been reported in amniocytes at 21 GW, and in peripheral blood and hair follicles sampled in a four-year old carrier (Chou et al., 2004).

1 **Comparison of mtDNA metabolism in m.3243A>G (MELAS) and m.8993T>G** 2 **(NARP) mutations throughout human embryofetal development**

3 Comparing mtDNA segregation data throughout human embryofetal development for
4 two different mtDNA mutations, namely, m.3243A>G/ MELAS and m.8993T>G/
5 NARP, highlights striking differences (Figure 3).

6 While all MELAS embryos herein reported, originating from 20 %-mutant load
7 carriers, are mutation-free or heteroplasmic up to 75% with an apparently random
8 distribution of heteroplasmy, the only two reports on m.8993T>G at Day 3-Day 5
9 embryonic stage indicated that the 3 NARP embryos from a 18-% mutant load carrier
10 were either wild-type or mutant homoplasmic (Steffann et al., 2006), the 5 remaining
11 ones carrying low levels of heteroplasmy (4-22%, Tajima et al., 2007). Though the
12 low number of embryos analyzed so far precludes drawing firm conclusion on a
13 putative difference of segregation between m.8993T>G and m.3243A>G molecules
14 during oogenesis, these apparently different patterns of segregation are however
15 substantiated by the few available analyses of primary oocytes from carriers of these
16 mutations (Blok et al., 1997; Brown et al., 2001). A wild-type (1/7) or mutant
17 homoplasmic state (6/7) was indeed the rule in the 7 NARP primary oocytes from a
18 50%-mutant load carrier, contrasting with the presence of heteroplasmy in 90% of 82
19 primary oocytes in a m.3243A>G carrier with a 8 %- mutant load in WBC. It can be
20 speculated from these data that bottleneck would be of different size between
21 m.3243A>G and m.8993T>G.

22 Whether a purifying selection operates in the human germline against
23 m.8993T>G and m.3243A>G is a matter of debate. Our data in early NARP embryos
24 (Steffann et al., 2006), those from the analysis of primary oocytes in a m8993T>G
25 carrier (Blok et al 1997), as well as our previous report on 2 fetuses with a mutant

load over 85 % from 2 m8993T>G carriers with a 30% mutant load in WBC (Steffann et al. 2007), clearly argue against such a negative selection for this mutation in human. As mentioned above, no conclusion can be drawn at this point on the occurrence of a purifying selection against m.3243A>G in the human germ line, owing to the limited number of data we achieved, all drawn from low (20 %) mutant load carriers. It has however to be emphasized that we never observed any fetus with a mutant load over 80% among the 8 pregnancies from 6 m.3243A>G carriers with a WBC mutant load equal or even higher than 30 % (patients 6-9, 11, 12, table 1), These data are difficult to reconcile with those from murine germline segregation studies indicating that mutations in protein coding genes of mtDNA are strongly selected against, whereas mutations affecting tRNA genes (such as m.3243A>G) are largely refractory from such a process (Fan et al, 2008, Stewart et al, 2008).

Regarding the somatic tissue development, we previously showed the existence of fetuses carrying m.8993T>G with various degrees of mutant loads, from 0% to 100 %, over the 10-GW stage of pregnancy until delivery (Steffann et al., 2007). m.8993T>G and m.3243A>G mutant loads remain at a steady-state level with time or across various tissues, thus supporting a random segregation of mutant mtDNA molecules throughout somatic embryo-fetogenesis irrespective of the mutation type.

In conclusion, one can speculate that the bottleneck size, **and possibly,** the mutant load threshold critical for embryo/fetus survival, varies among mtDNA mutations, thus hampering genetic counselling and PND/PGD procedures in mitochondriopathies resulting from “private” mtDNA mutations. To test this speculation, we will need to collect data on mtDNA mutant loads for other rarer mtDNA mutations.

1
2
3 1
4
5
6 2
7
8
9 3 **Acknowledgments**

10
11 4
12
13 5 We gratefully acknowledge Dr C Elie and Dr JP Jais for their assistance with the
14
15
16 6 statistics. We also thanks the families for their cooperation. This research was
17
18 7 supported, in part, by grants from l'Association Française contre les Myopathies
19
20 8 (AFM), l'Agence de Biomédecine, l'INSERM, and the European network Mitocircle.
21
22
23 9 S.M was funded by l'AFM
24

25 10
26
27
28 11 **Web resources**

29
30 12
31
32
33 13 Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim>

References

- Bergstrom CT, Pritchard J. 1998. Germline bottlenecks and the evolutionary maintenance of mitochondrial genomes. *Genetics* 149(4):2135-46.
- Blok RB, Gook DA, Thorburn DR, Dahl HH. 1997. Skewed segregation of the mtDNA nt 8993 (T-->G) mutation in human oocytes. *Am J Hum Genet* 60(6):1495-501.
- Bouchet C, Steffann J, Corcos J, Monnot S, Paquis V, Rotig A, Lebon S, Levy P, Royer G, Giurgea I, Gigarel N, Benachi A, Dumez Y, Munnich A, Bonnefont JP.. 2006. Prenatal diagnosis of myopathy, encephalopathy, lactic acidosis, and stroke-like syndrome: contribution to understanding mitochondrial DNA segregation during human embryofetal development. *J Med Genet* 43(10):788-92.
- Brown DT, Samuels DC, Michael EM, Turnbull DM, Chinnery PF. 2001. Random genetic drift determines the level of mutant mtDNA in human primary oocytes. *Am J Hum Genet* 68(2):533-6.
- Cao L, Shitara H, Horii T, Nagao Y, Imai H, Abe K, Hara T, Hayashi J, Yonekawa H. 2007. The mitochondrial bottleneck occurs without reduction of mtDNA content in female mouse germ cells. *Nat Genet* 39(3):386-90.
- Cao L, Shitara H, Sugimoto M, Hayashi J, Abe K, Yonekawa H. 2009. New evidence confirms that the mitochondrial bottleneck is generated without reduction of mitochondrial DNA content in early primordial germ cells of mice. *PLoS Genet* 5(12):e1000756.
- Cardaioli E, Fabrizi GM, Grieco GS, Dotti MT, Federico A. 2000. Heteroplasmy of the A3243G transition of mitochondrial tRNA(Leu(UUR)) in a MELAS case and in a 25-week-old miscarried fetus. *J Neurol* 247(11):885-7.
- Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. 1997. Molecular pathology of

- 1
2
3 1 MELAS and MERRF. The relationship between mutation load and clinical
4
5 2 phenotypes. *Brain* 120 (Pt 10):1713-21.
6
7
8 3 Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. 1998. Genetic counseling and
9
10 4 prenatal diagnosis for mtDNA disease. *Am J Hum Genet* 63(6):1908-11.
11
12 5 Chinnery PF, Zwiijnenburg PJ, Walker M, Howell N, Taylor RW, Lightowlers RN,
13
14 6 Bindoff L, Turnbull DM. 1999. Nonrandom tissue distribution of mutant mtDNA.
15
16 7 *Am J Med Genet* 85(5):498-501.
17
18 8 Chou YJ, Ou CY, Hsu TY, Liou CW, Lee CF, Tso DJ, Wei YH. 2004. Prenatal
19
20 9 diagnosis of a fetus harboring an intermediate load of the A3243G mtDNA
21
22 10 mutation in a maternal carrier diagnosed with MELAS syndrome. *Prenat Diagn*
23
24 11 24(5):367-70.
25
26
27
28
29 12 Craven L, Tuppen HA, Greggains GD, Harbottle SJ, Murphy JL, Cree LM, Murdoch
30
31 13 AP, Chinnery PF, Taylor RW, Lightowlers RN, Herbert M, Turnbull DM. 2010.
32
33 14 Pronuclear transfer in human embryos to prevent transmission of
34
35 15 mitochondrial DNA disease. *Nature* 465(7294):82-5.
36
37
38
39 16 Cree LM, Samuels DC, de Sousa Lopes SC, Rajasimha HK, Wonnapijit P, Mann JR,
40
41 17 Dahl HH, Chinnery PF. 2008. A reduction of mitochondrial DNA molecules
42
43 18 during embryogenesis explains the rapid segregation of genotypes. *Nat Genet*
44
45 19 40(2):249-54.
46
47
48
49 20 Cui XF, Li HH, Goradia TM, Lange K, Kazazian HH, Jr., Galas D, Arnheim N. 1989.
50
51 21 Single-sperm typing: determination of genetic distance between the G
52
53 22 gamma-globin and parathyroid hormone loci by using the polymerase chain
54
55 23 reaction and allele-specific oligomers. *Proc Natl Acad Sci U S A* 86(23):9389-
56
57 24 93.
58
59
60 25 Dean NL, Battersby BJ, Ao A, Gosden RG, Tan SL, Shoubbridge EA, Molnar MJ.

2003. Prospect of preimplantation genetic diagnosis for heritable mitochondrial DNA diseases. *Mol Hum Reprod* 9(10):631-8.
- Fan W, Waymire KG, Narula N, Li P, Rocher C, Coskun PE, Vannan MA, Narula J, Macgregor GR, Wallace DC. 2008. A mouse model of mitochondrial disease reveals germline selection against severe mtDNA mutations. *Science* 319(5865):958-62.
- Ferlin T, Landrieu P, Rambaud C, Fernandez H, Dumoulin R, Rustin P, Mousson B. 1997. Segregation of the G8993 mutant mitochondrial DNA through generations and embryonic tissues in a family at risk of Leigh syndrome. *J Pediatr* 131(3):447-9.
- Frederiksen AL, Andersen PH, Kyvik KO, Jeppesen TD, Vissing J, Schwartz M. 2006. Tissue specific distribution of the 3243A->G mtDNA mutation. *J Med Genet* 43(8):671-7.
- Gigarel N, Frydman N, Burlet P, Kerbrat V, Steffann J, Frydman R, Munnich A, Ray PF. 2004. Single cell co-amplification of polymorphic markers for the indirect preimplantation genetic diagnosis of hemophilia A, X-linked adrenoleukodystrophy, X-linked hydrocephalus and incontinentia pigmenti loci on Xq28. *Hum Genet* 114(3):298-305.
- Gigarel N, Ray PF, Burlet P, Frydman N, Royer G, Lebon S, Bonnefont JP, Frydman R, Munnich A, Steffann J. 2005. Single cell quantification of the 8993T>G NARP mitochondrial DNA mutation by fluorescent PCR. *Mol Genet Metab* 84(3):289-92.
- Goto Y, Horai S, Matsuoka T, Koga Y, Nihei K, Kobayashi M, Nonaka I. 1992. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and

- mitochondrial DNA mutation. *Neurology* 42(3 Pt 1):545-50.
- Harding AE, Holt IJ, Sweeney MG, Brockington M, Davis MB. 1992. Prenatal diagnosis of mitochondrial DNA8993 T----G disease. *Am J Hum Genet* 50(3):629-33.
- Inoue K, Nakada K, Ogura A, Isobe K, Goto Y, Nonaka I, Hayashi JI. 2000. Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes. *Nat Genet* 26(2):176-81.
- Jenuth JP, Peterson AC, Fu K, Shoubridge EA. 1996. Random genetic drift in the female germline explains the rapid segregation of mammalian mitochondrial DNA. *Nat Genet* 14(2):146-51.
- Jeppesen TD, Schwartz M, Frederiksen AL, Wibrand F, Olsen DB, Vissing J. 2006. Muscle phenotype and mutation load in 51 persons with the 3243A>G mitochondrial DNA mutation. *Arch Neurol* 63(12):1701-6.
- Laipis PJ, Van de Walle MJ, Hauswirth WW. 1988. Unequal partitioning of bovine mitochondrial genotypes among siblings. *Proc Natl Acad Sci U S A* 85(21):8107-10.
- Leshinsky-Silver E, Perach M, Basilevsky E, HersHKovitz E, Yanoov-Sharav M, Lerman-Sagie T, Lev D. 2003. Prenatal exclusion of Leigh syndrome due to T8993C mutation in the mitochondrial DNA. *Prenat Diagn* 23(1):31-3.
- Lin DP, Huang CC, Wu HM, Cheng TC, Chen CI, Lee MS. 2004. Comparison of mitochondrial DNA contents in human embryos with good or poor morphology at the 8-cell stage. *Fertil Steril*. 81(1):73-9.
- Maagaard A, Holberg-Petersen M, Kvittingen EA, Sandvik L, Bruun JN. 2006. Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naïve patients. *HIV Med*. 7(1):53-8.

- 1 Manouvrier S, Rotig A, Hannebique G, Gheerbrandt JD, Royer-Legrain G, Munnich
2 A, Parent M, Grunfeld JP, Largilliere C, Lombes A, Bonnefont JP. 1995. Point
3 mutation of the mitochondrial tRNA(Leu) gene (A 3243 G) in maternally
4 inherited hypertrophic cardiomyopathy, diabetes mellitus, renal failure, and
5 sensorineural deafness. *J Med Genet* 32(8):654-6.
- 6 Marchington DR, Macaulay V, Hartshorne GM, Barlow D, Poulton J. 1998. Evidence
7 from human oocytes for a genetic bottleneck in an mtDNA disease. *Am J Hum*
8 *Genet* 63(3):769-75.
- 9 Marchington DR, Scott-Brown M, Barlow DH, Poulton J. 2006. Mosaicism for
10 mitochondrial DNA polymorphic variants in placenta has implications for the
11 feasibility of prenatal diagnosis in mtDNA diseases. *Eur J Hum Genet*
12 14(7):816-23.
- 13 Marchington D, Malik S, Banerjee A, Turner K, Samuels D, Macaulay V, Oakeshott
14 P, Fratter C, Kennedy S, Poulton J. 2010 Information for genetic management
15 of mtDNA disease: sampling pathogenic mtDNA mutants in the human
16 germline and in placenta. *J Med Genet* 47(4):257-61.
- 17 Matthews PM, Hopkin J, Brown RM, Stephenson JB, Hilton-Jones D, Brown GK.
18 1994. Comparison of the relative levels of the 3243 (A-->G) mtDNA mutation
19 in heteroplasmic adult and fetal tissues. *J Med Genet* 31(1):41-4.
- 20 McArthur SJ, Leigh D, Marshall JT, de Boer KA, Jansen RP. 2005. Pregnancies and
21 live births after trophectoderm biopsy and preimplantation genetic testing of
22 human blastocysts. *Fertil Steril* 84(6):1628-36.
- 23 Parfait B, Rustin P, Munnich A, Rotig A. 1998. Co-amplification of nuclear
24 pseudogenes and assessment of heteroplasmy of mitochondrial DNA
25 mutations. *Biochem Biophys Res Commun* 247(1):57-9.

- 1 Petruzzella V, Moraes CT, Sano MC, Bonilla E, DiMauro S, Schon EA. 1994.
2
3
4
5
6 2 Extremely high levels of mutant mtDNAs co-localize with cytochrome c
7
8 3 oxidase-negative ragged-red fibers in patients harboring a point mutation at nt
9
10 4 3243. *Hum Mol Genet* 3(3):449-54.
11
12
13 5 Pettman R, Hurley T, Addis J, Robinson B, Scott H, Kronick JB. 2007. Prenatal
14
15 6 diagnosis by amniocentesis and chorionic villus biopsy of mtDNA mutation
16
17 7 8993T > G. *J Inherit Metab Dis* 30(3):404.
18
19
20 8 Rajasimha HK, Chinnery PF, Samuels DC. 2008. Selection against pathogenic
21
22 9 mtDNA mutations in a stem cell population leads to the loss of the 3243A-->G
23
24 10 mutation in blood. *Am J Hum Genet* 82(2):333-43.
25
26
27 11 Roze D, Rousset F, Michalakis Y. 2005. Germline bottlenecks, biparental inheritance
28
29 12 and selection on mitochondrial variants: a two-level selection model. *Genetics*
30
31 13 170(3):1385-99.
32
33
34 14 Saitoh S, Momoi MY, Yamagata T, Nakauchi H, Nihei K, Fujii M. 1999. Single-cell
35
36 15 analysis of mitochondrial DNA in patients and a carrier of the tRNA(Leu)(UUR)
37
38 16 gene mutation. *J Inherit Metab Dis* 22(5):608-14.
39
40
41 17 Sasarman F, Antonicka H, Shoubridge EA. 2008. The A3243G tRNA^{Leu}(UUR)
42
43 18 MELAS mutation causes amino acid misincorporation and a combined
44
45 19 respiratory chain assembly defect partially suppressed by overexpression of
46
47 20 EFTu and EFG2. *Hum Mol Genet* 17(23):3697-707.
48
49
50 21 Silvestri G, Rana M, Odoardi F, Modoni A, Paris E, Papacci M, Tonali P, Servidei S.
51
52 22 2000. Single-fiber PCR in MELAS(3243) patients: correlations between
53
54 23 intratissue distribution and phenotypic expression of the mtDNA(A3243G)
55
56 24 genotype. *Am J Med Genet* 94(3):201-6.
57
58
59 25 Steffann J, Frydman N, Gigarel N, Burlet P, Ray PF, Fanchin R, Feyereisen E,
60

- 1
2
3 1 Kerbrat V, Tachdjian G, Bonnefont JP, Frydman R, Munnich A. 2006. Analysis
4
5 2 of mtDNA variant segregation during early human embryonic development: a
6
7 3 tool for successful NARP preimplantation diagnosis. *J Med Genet* 43(3):244-7.
8
9
10 4 Steffann J, Gigarel N, Corcos J, Bonniere M, Encha-Razavi F, Sinico M, Prevot S,
11
12 5 Dumez Y, Yamgnane A, Frydman R, Munnich A, Bonnefont JP. 2007. Stability
13
14 6 of the m.8993T->G mtDNA mutation load during human embryofetal
15
16 7 development has implications for the feasibility of prenatal diagnosis in NARP
17
18 8 syndrome. *J Med Genet* 44(10):664-9.
19
20
21 9 Stewart JB, Freyer C, Elson JL, Wredenberg A, Cansu Z, Trifunovic A, Larsson NG.
22
23 10 2008. Strong purifying selection in transmission of mammalian mitochondrial
24
25 11 DNA. *PLoS Biol* 6(1):e10.
26
27
28 12 Tajima H, Sueoka K, Moon SY, Nakabayashi A, Sakurai T, Murakoshi Y, Watanabe
29
30 13 H, Iwata S, Hashiba T, Kato S, Goto Y, Yoshimura Y. 2007. The development
31
32 14 of novel quantification assay for mitochondrial DNA heteroplasmy aimed at
33
34 15 preimplantation genetic diagnosis of Leigh encephalopathy. *J Assist Reprod*
35
36 16 *Genet* 24(6):227-32.
37
38
39 17 Tanno Y, Yoneda M, Nonaka I, Tanaka K, Miyatake T, Tsuji S. 1991. Quantitation of
40
41 18 mitochondrial DNA carrying tRNA^{Lys} mutation in MERRF patients. *Biochem*
42
43 19 *Biophys Res Commun* 179(2):880-5.
44
45
46 20 Tokunaga M, Mita S, Murakami T, Kumamoto T, Uchino M, Nonaka I, Ando M. 1994.
47
48 21 Single muscle fiber analysis of mitochondrial myopathy, encephalopathy, lactic
49
50 22 acidosis, and stroke-like episodes (MELAS). *Ann Neurol* 35(4):413-9.
51
52
53 23 Urata M, Koga-Wada Y, Kayamori Y, Kang D. 2008. Platelet contamination causes
54
55 24 large variation as well as overestimation of mitochondrial DNA content of
56
57 25 peripheral blood mononuclear cells. *Ann Clin Biochem.* 45(Pt5):513-4
58
59
60

- Uusimaa J, Moilanen JS, Vainionpaa L, Tapanainen P, Lindholm P, Nuutinen M, Lopponen T, Maki-Torkko E, Rantala H, Majamaa K. 2007. Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A>G mutation in children. *Ann Neurol* 62(3):278-87.
- van den Ouweland JM, Lemkes HH, Ruitenbeek W, Sandkuijl LA, de Vijlder MF, Struyvenberg PA, van de Kamp JJ, Maassen JA. 1992. Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. *Nat Genet* 1(5):368-71.
- Wai T, Teoli D, Shoubridge EA. 2008. The mitochondrial DNA genetic bottleneck results from replication of a subpopulation of genomes. *Nat Genet* 40(12):1484-8.
- White SL, Shanske S, Biros I, Warwick L, Dahl HM, Thorburn DR, Di Mauro S. 1999. Two cases of prenatal analysis for the pathogenic T to G substitution at nucleotide 8993 in mitochondrial DNA. *Prenat Diagn* 19(12):1165-8.
- Whittaker RG, Blackwood JK, Alston CL, Blakely EL, Elson JL, McFarland R, Chinnery PF, Turnbull DM, Taylor RW. 2009. Urine heteroplasmy is the best predictor of clinical outcome in the m.3243A>G mtDNA mutation. *Neurology* 72(6):568-9.
- Wonnapijit P, Chinnery PF, Samuels DC. 2010. Previous estimates of mitochondrial DNA mutation level variance did not account for sampling error: comparing the mtDNA genetic bottleneck in mice and humans. *Am J Hum Genet* 86(4):540-50.
- Wonnapijit P, Chinnery PF, Samuels DC. 2008. The distribution of mitochondrial DNA heteroplasmy due to random genetic drift. *Am J Hum Genet* 83(5):582-93.

FIGURES LEGENDS

Figure 1. Standardization of m.3243A>G load assessment

The rate of m.3243A>G heteroplasmy was assessed by semi-quantitative fluorescent PCR using 10 samples containing various proportions of mutant plasmid. Each sample comprised 10^6 mtDNA copies. Each value is the mean of three independent experiments. Bars depict standard deviations. WT: wild-type DNA.

Figure 2. Distribution of m.3243A>G mutation levels across isolated cells

MELAS mutant load was assessed in trophoblastic cells sampled at 10GW (open boxes) and amniocytes sampled at 14 (hatched boxes) or 30 (filled boxes) GW in 6 fetuses (numbering refers to Table 4). n: number of analyzed cells. Each box depicts the mean mutant load plus (top bar), and minus 1 standard deviation (bottom bar) for a given cell pool. Whiskers depict maximal (top) and minimal (bottom) values for each sample. Central bar: median. * mean mutant load assessed on the whole chorionic villi, or amniocyte sample.


Figure 3. Comparative distribution of m.3243A>G and m.8993T>G/C mutant loads in mature oocytes, blastomeres, and fetal tissues

◇ m.3243A>G (MELAS syndrome), ○ m.8993T>G/C (NARP syndrome). Scatter plots are drawn from personal (black symbols) and literature data (white symbols: Harding et al.1992; Matthews et al., 1994; Blok et al., 1997; Ferlin et al., 1997; White et al., 1999; Cardaioli et al., 2000; Brown et al., 2001; Leshinsky-Silver et al., 2003; Chou et al., 2004 ; Pettman et al., 2007; Tajima et al., 2007). Each point depicts one oocyte or one individual (embryo or fetus). All oocyte values were from a single


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 carrier of m.3243A>G (Brown et al., 2001) or m.8993T>G (Blok et al., 1997). When
2 several values were available for one individual, the average heteroplasmy value was
3 selected. Both Day 3 and 14GW values were available (and therefore depicted) for
4 one “NARP” (0% and 0%) and one “MELAS” individual (5% and 5%) only. All other
5 Day 3-Day 5 and 8-25 GW (gestation weeks) values were from distinct individuals.


For Peer Review



254x190mm (96 x 96 DPI)




254x190mm (96 x 96 DPI)



254x190mm (96 x 96 DPI)

Supplementary Figure 1. Standardization of m.3243A>G load assessment over a 10²-10⁵ mtDNA copy range

The rate of m.3243A>G heteroplasmy was assessed by semi-quantitative fluorescent PCR using 5 samples containing various proportions of mutant plasmid (11%, 33%, 50%, 67%, 89%) and 5 different template amounts (10², 10³, 10⁴, 10⁵, 10⁶). Values achieved with 10⁶ copies are displayed as Fig 1. Each dot depicts the result of one experiment. Y axis: expected percentage of m.3243A>G mutant load. X axis: observed percentage of m.3243A>G mutant load.



Supplementary Figure 2. Distribution of inter cell dispersion of m.3243A>G mutant load according to the heteroplasmy rate of overall cell pools

Data are represented as standard deviation of the mean mutant load vs mean heteroplasmy rate for each pool. ◇ prenatal cell pools: syncytiotrophoblasts and amniocytes (data from Table 2 and Figure 2); Black symbols: postnatal cell pools: ● lymphocytes (data from Table 2), ▲ muscle fibers (data from Petruzella et al., 1994; Tokunaga et al., 1994; Silvestri et al., 2000). Each symbol reflects the analysis of one cell pool for one individual.




Table 1. Maternal m.3243A>G mutant load

	Patient	Mutant load (%)		
		WBC	OMC	UTC
A	1	20	30	65
	2	20	27	30
	3	20	40	50
	4	7	8	15
	5	5	10	35
	6	30	50	80
	7	30		70
	8	40		55
B	9	39	48	
	10	20		
	11	63		
	12	34	45	80
	13	21		

A, Patients analyzed in this study. **B**, Patients reported elsewhere: (9) Matthews et al., 1994, (10) Cardaioli et al., 2000 , (11) Chou et al., 2004, (12, 13) our group (Bouchet et al., 2006). WBC, white blood cells; OMC, oral mucosa cells; UTC, urinary tract cells.

Table 2. m.3243A>G mutant load in single cells of various origins

	Lymphocytes	Syncytiotrophoblasts/amniocytes	Muscle fibers^a
Number of patients	5	5	8
Number of cell pools	5	10	21
Total cell number	84	147	341
Heteroplasmy level (mean \pm SD)	16.2 \pm 8 %	34.3 \pm 13 %	78.5 \pm 17 %
Correlation coefficient (p)	0.92 (< 0.05)	0.81 (<0.05)	0.84 (<0.01)
Slope \pm SD	1.14 \pm 0.28	0.13 \pm 0.03	-0.38 \pm 0.05

^a calculation from data by Tokunaga et al., 1994; Petruzella et al., 1994; Silvestri et al., 2000

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. m3243A>G mutant load in preimplantation embryos					
Patient	Embryo	Single blastomere		Overall embryo Median	Mean (±SD)
		Blastomere 1	Blastomere 2		
1	1			18±1 (n=6)	↑
	2			23±2 (n=5)	23%
	3			50±3 (n=3)	↓
2	1	0 ^a	0		↑
	2	0	0		
	3	0	0	0	
	4			0	
	5			0	
	6			0	
	7	5	5		
	8	7	8		
	9	12	14		
	10	13	13	I ^b T: 15	
	11	13	16		
	12	17	22	15	
	13	14	15	16±2 (n=11)	
	14	a	25	23	
	15	27	27	23	
	16			28	
	17	15	21	30	
	18	40	41	37	37%
	19			42	
	20			42	
	21			43	
	22			47	
	23	51	55	48	
	24			50	
	25			50	
	26	39	40	50	
	27	54	55	50	
	28			55	
	29			60	
	30	55	55	62	
	31	63	66	63	
	32	51	54	66	
	33	67	68	74	
	34	72	77		
	35	69	71	75	↓
Patient numbering refers to Table 1. Individual values i) represent the heteroplasmy level of 2 single blastomeres or of embryos in toto, ii) are expressed as mean ± SD when more than two blastomeres from one embryo were analyzed (number of analyzed blastomeres in brackets). Embryo 10 from family 2 was separated in two parts before PCR analysis, ie, the inner cell mass (I), and the trophectoderm (T). Calculation of "overall mean value" and "overall median value" took into account either the mean of the values achieved trough analysis of all blastomeres when only blastomeres were available, or values from embryos only in other cases. ^a detection threshold:2%; ^b PCR failure.					

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1

For Peer Review

Table 4. m.3243A>G load in extra-embryonic and embryo-fetal tissues

	Patient	Fetus	CVS	AF1	AF2	Muscle	Liver	Heart	Skin	Kidney	Lung	Gut	Brain	Optic nerve	Thymus	Umbilical cord	Placenta	Cord blood
A	2	2a	77±3			75±1.5		74±3.2			74±0						73, 75 ^a	
		2b	59±6			42±1		41±2	42±2	43±2	43±0.3						57±2 ^b	
		2c		4±0													15±5 ^c	5±1
	3	3	17±3	16±0.5													22±6 ^d	16±0
	4	4		0														0
	5	5a	20±0.5	15±3	15±2													
		5b		70±1			72±2		73±0	68±2					72±1			
		5c	4±0.6															
	6	6	32±1	28±1														
	7	7a				79±0	78±0.6	77±0.9	78±0.3	79±0	79±0.3					78±1.7	78±1.7	
		7b	79±2															
	8	8	49±0.7															
B	9	9				55±1	52±4	54±3	51±3	56±5		53±4	52±3	51±3			55±3	
	10	10				50	50							50				
	11	11			67													
	12	12a	35	33	29													
		12b	31	23	26													
	13	13a	60	63														
		13b	0	0														
		13c	0	0														

A. Fetuses analyzed in this study. Chorionic villi (CVS) were sampled at 10 GW, and amniotic fluids (AF) at 14 (AF1) and 30 (AF2) GW, respectively. The other tissues were sampled at 12 GW (fetuses 2a and 2b), or at 19, 20, 24, and 25 GW for fetuses 5b, 7, 9, and 10, respectively, and at term for fetuses 2c and 3. Cord blood was sampled at birth for fetuses 2c (38GW), 3 (37GW) and 4 (39 GW). All assays were carried out in triplicate. Values are expressed as mean ±SD. Placenta values measured on ^a2, ^b6, ^c10, and ^d18 separate biopsies, respectively (SD: intersample variation). **B.** Fetuses reported elsewhere: (9) Matthews et al., 1995, (10) Cardaioli et al., 2000, (11) Chou et al., 2004, (12, 13) our group (Bouchet et al., 2006). In boldface: patients born after PGD or PND.

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 5. Comparative analysis of mutation levels in preimplantation embryos from patient 2 and primary oocytes from a published report

	Patient 2		Brown et al., 2001	
Sample size (n)	35		82	
Mean mutation level (p_0)	33.7%	[25.8% – 42.1%]	12.6%	[10% - 15%]
Mutation level variance (V)	0.06	[0.037 – 0.086]	0.014	[0.009 – 0.020]
Normalized variance ($V/(p_0(1-p_0))$)	0.27	[0.18 – 0.38]	0.13	[0.09 – 0.17]
Bottleneck parameter (b)	0.72	[0.62 – 0.82]	0.87	[0.83 – 0.91]
Probability of fixing on wild-type	8.4%	[1.5% - 19%]	14%	[6% - 24%]
Probability of fixing on the mutant	0.4%	[0 – 2.0%]	2×10^{-7}	[0 – 1×10^{-6}]
Probability of having > 60% mutant	17%	[7% - 27%]	0.3%	[0.02% - 0.8%]

Values are given as mean [95% confidence intervals].
The distribution of the mutation level values from Patient 2 was consistent with the Kimura distribution (p-value of 0.53 by KS test).